La esclerosis sistémica (ES) puede afectar al pericardio, el miocardio, las arterias coronarias, el sistema de conducción y las válvulas cardíacas. La presencia. El objetivo de esta revisión es analizar las diferencias en la epidemiología, las manifestaciones clínicas y la gravedad de la esclerosis sistémica en los. La esclerosis sistémica es una enfermedad autoinmune del tejido conectivo, que se caracteriza por un depósito excesivo de tejido colágeno y otros.

Author: Moramar Groshicage
Country: Georgia
Language: English (Spanish)
Genre: Love
Published (Last): 6 May 2009
Pages: 274
PDF File Size: 5.20 Mb
ePub File Size: 17.7 Mb
ISBN: 875-1-90644-686-1
Downloads: 42393
Price: Free* [*Free Regsitration Required]
Uploader: Milar

Eur J Clin Invest, 18pp. Pathologic observations in systemic sclerosis scleroderma. Assessment of microvascular changes in Raynaud’s phenomenon and connective tissue disease using colour Doppler ultrasound. Rheum Dis Clin North Am, 20pp. Disease severity of patients with systemic sclerosis over period of 14 years: Arthritis Rheum, sistemiicapp.

Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis.

Lancet,pp. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Gastrointestinal manifestation of systemic sclerosis. Clin Exp Rheumatol, 23pp. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. La videocapillaroscopia periungueale nella sclerosis sistemica: Gastroenterol Clin North Am, 27pp.

TOP Related Articles  COURS J2ME EBOOK

Rheumatology Oxford40pp. Digital ulcers in patients with systemic sclerosis. eslerosis

N Engl J Med,pp. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Sistmeica phenomenon. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: Z Rheumatol, 63pp. Ann Intern Med,pp. A multicenter, placebo-controlled, doubleblind study.

Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Prognostic factors of low bone mineral density in systemic sclerosis.

Clin Exp Rheumatol, 1pp. These lesions are extremely painful, heal slowly and lead to substantial functional disability.

Severe organ involvement in systemic sclerosis with diffuse scleroderma. Metoclopramide response in patients with early diffuse systemic sclerosis. Comparative esophageal and anorectal motility in scleroderma.

Intravenous N-Acetylcysteine for treatment of Raynaud’s secondary to systemic sclerosis: Thyroid dysfunction in a prospectively followed esclerosus of patients with progressive systemic sclerosis. Prevalence of Raynaud phenomenon in general practice in the east of Spain. Role of alfa-adrenoreceptor subtypes mediating sympathetic vasoconstriction in human digits. Osteoporosis — less than expected in patients with scleroderma.


Epidemiología. Diferencias étnicas en la esclerosis sistémica – ScienceDirect

Systemic sclerosis is an autoimmune disease of the connective tissue characterized by an excessive deposit of collagen and other components of the extracellular matrix in the skin as well as in other internal organs, eesclerosis in lung, gastrointestinal tract and kidney. Curr Rheumatol Rep, 7pp. Ann Rheum Dis, 67pp.

Double-blind, placebo controlled study of prazosin in Raynaud’s phenomenon. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: El uso de estos medicamentos ha sido un gran avance en el tratamiento de la esclerodermia.